New hope for Tough-to-Treat lung cancer: targeted drug enters final testing phase
NCT ID NCT07242274
Summary
This study is testing whether a new targeted drug, JMKX001899, works better than standard chemotherapy (docetaxel) for people with advanced lung cancer that has a specific genetic change called KRAS G12C. The trial will involve about 472 adults whose cancer has worsened after previous treatments. The main goal is to see if the new drug can help control the cancer for longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Beijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.